The current study investigated the impact of FGFR inhibitors on IFN-γ-induced PD-L1 expression and their potential effect on antitumor immunity in luminal-type BC cells harboring FGFR3-TACC3 fusions. The gene discussed is FGFR3; the disease is breast cancer.